ACACIA PHARMA LIMITED

• ⚠

  Material uncertainty over going concern

  The matters described above indicate the existence of a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

1. ACACIA PHARMA LIMITED 2007-02-02 → present
2. LETTERHOOD LIMITED 2006-09-14 → 2007-02-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The matters described above indicate the existence of a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. ACACIA PHARMA LIMITED · parent
   1. Acacia Pharma, Inc. 1% · USA · Sale and marketing of pharmaceuticals

Significant events

• “On 9 June 2022, the acquisition of Acacia Pharma Group Limited (formerly Acacia Pharma Group plc), the Company's parent, by Eagle Pharmaceuticals, Inc. by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 became effective.”
• “On 28 February 2024, the Company's parent, Eagle Pharmaceuticals, Inc. approved and began implementing a plan designed to improve operational efficiencies and realign Eagle Pharmaceuticals, Inc.'s sales and marketing expenditures (the "Realignment Plan").”
• “On 1 October 2024, Eagle Pharmaceuticals, Inc. received a notice from the hearings panel of Nasdaq stating that it had determined to delist Eagle Pharmaceuticals, Inc.'s common stock from Nasdaq...”
• “On 27 November 2024, Eagle Pharmaceuticals, Inc. filed a Post-Effective Amendment with the Securities and Exchange Commission SEC to terminate the offerings of its securities pursuant to the Registration Statement.”
• “On March 31, 2025, Eagle Pharmaceuticals, Inc. used the net proceeds from the Blue Owl Agreement to repay, in full, all amounts outstanding under the credit agreement with its lender, JPMorgan Chase Bank, N.A.”
• “On January 24, 2025, Eagle Pharmaceuticals, Inc. informed Nasdaq of its intent to file Form 15 with the SEC to finalize the delisting of its common stock from the Nasdaq Global.”
• “In April 2025, Eagle Pharmaceuticals, Inc. determined certain net assets related to the Acacia business, including its BARHEMSYS® and BYFAVO® products, met the criteria required to be classified as held-for-sale.”
• “In June 2024 the Company received a notice from the licensor of BYFAVO® purporting to terminate the license agreement with respect to BYFAVO®, effective August 19, 2024...”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +84.7%

  £992,000 → £1,832,000

• Cash

  +94.1%

  £1,344,000 → £2,609,000

• Net assets

  -1.7%

  -£166,475,000 → -£169,300,000

• Employees

  —

  Not reported

• Operating profit

  +95%

  -£45,724,000 → -£2,308,000

• Profit before tax

  +93.6%

  -£44,261,000 → -£2,825,000

• Wages

  -100%

  £105,000 → £0

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers